Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of baricitinib in rheumatoid arthritis after inadequate response to TNF inhibitors
jRCT2080222110Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Baricitinib + background cDMARD with Placebo + background cDMARD (2 arms). Started Jun 2013; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222110.